Tandem Diabetes Care, Inc. TNDM

Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on the Sigi tubeless patch pump. Tandem is also developing a fully closed-loop algorithm for its pumps. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 3 to 7 days.

TNDM hizo una agrupación de acciones (split inverso) de 1:10 el 10 de octubre de 2017: cada 10 acciones se juntaron en una. Bajó la cantidad de acciones y subió su precio, pero no el valor total de la inversión.

• Zacks Investment Research 9 sept

  Reasons to Retain Tandem Diabetes Stock in Your Portfolio Now

  Tandem Diabetes (TNDM) is positioned for growth with its expanding product roadmap including the Mobi tubeless pump, new CGM integrations, and AIDANET closed-loop program. The company's pay-as-you-go reimbursement model aims to lower upfront barriers and boost recurring supply revenue. However, macroeconomic pressures, reimbursement sensitivity, competitive threats, and the impact of GLP-1 drugs on insulin therapy demand pose significant headwinds to sustained profitability.

  

• Zacks Investment Research 31 ago

  Aging Population Drives Healthcare Growth: Stocks to Watch

  The global aging population is reshaping healthcare investment opportunities, with the geriatric care services market projected to grow from $1.24 trillion in 2025 to $2.16 trillion by 2034. Healthcare companies are capitalizing on this demographic shift through innovations in diabetes care, cardiovascular treatments, robotic surgery, and digital health solutions. Key players like AbbVie, Tandem Diabetes Care, Amgen, Stryker, and Boston Scientific are advancing AI-enabled technologies and specialized treatments for age-related conditions.